Biblio

Export 796 results:
Author Title Type [ Year(Desc)]
Filters: First Letter Of Keyword is P  [Clear All Filters]
2024
O. Almkvist, Larsson, M., and Graff, C., “Odor Identification Across Time in Mutation Carriers and Non-Carriers in Autosomal-Dominant Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 2, pp. 587-598, 2024.
P. Du, Zhang, X., Lian, X., Holscher, C., and Xue, G., “O-GlcNAcylation and Its Roles in Neurodegenerative Diseases.”, J Alzheimers Dis, vol. 97, no. 3, pp. 1051-1068, 2024.
P. Du, Zhang, X., Lian, X., Holscher, C., and Xue, G., “O-GlcNAcylation and Its Roles in Neurodegenerative Diseases.”, J Alzheimers Dis, vol. 97, no. 3, pp. 1051-1068, 2024.
A. M. R. McLaren and Kawaja, M. D., “Olfactory Dysfunction and Alzheimer's Disease: A Review.”, J Alzheimers Dis, vol. 99, no. 3, pp. 811-827, 2024.
J. Maters, van der Steen, J. T., de Vugt, M. E., Bakker, C., and Koopmans, R. T. C. M., “Palliative Care in Nursing Home Residents with Young-Onset Dementia: Professional and Family Caregiver Perspectives.”, J Alzheimers Dis, vol. 97, no. 2, pp. 573-586, 2024.
X. Morató, Tartari, J. Pablo, Pytel, V., and Boada, M., “Pharmacodynamic and Clinical Effects of Ginkgo Biloba Extract EGb 761 and Its Phytochemical Components in Alzheimer's Disease.”, J Alzheimers Dis, vol. 101, no. s1, pp. S285-S298, 2024.
X. Morató, Tartari, J. Pablo, Pytel, V., and Boada, M., “Pharmacodynamic and Clinical Effects of Ginkgo Biloba Extract EGb 761 and Its Phytochemical Components in Alzheimer's Disease.”, J Alzheimers Dis, vol. 101, no. s1, pp. S285-S298, 2024.
C. Cressot, Vrillon, A., Lilamand, M., Francisque, H., Méauzoone, A., Hourregue, C., Dumurgier, J., Marlinge, E., Paquet, C., and Cognat, E., “Psychosis in Neurodegenerative Dementias: A Systematic Comparative Review.”, J Alzheimers Dis, vol. 99, no. 1, pp. 85-99, 2024.
O. Snytnikova, Telegina, D., Savina, E., Tsentalovich, Y., and Kolosova, N., “Quantitative Metabolomic Analysis of the Rat Hippocampus: Effects of Age and of the Development of Alzheimer's Disease-Like Pathology.”, J Alzheimers Dis, vol. 99, no. s2, pp. S327-S344, 2024.
A. J. Espay, Herrup, K., Imbimbo, B. P., Kepp, K. P., and Daly, T., “Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42.”, J Alzheimers Dis, vol. 99, no. 3, pp. 877-881, 2024.
K. Ishii, Yamada, T., Hanaoka, K., Kaida, H., Kojita, Y., Kono, A., Hanada, K., Saigoh, K., Sakuta, S., Hashimoto, M., Kato, T., and Nakamura, A., “Regional differences in glucose metabolic decline and tau deposition in the Alzheimer's continuum brain.”, J Alzheimers Dis, vol. 102, no. 1, pp. 228-236, 2024.
H. Stevens Smith, Robinson, J. O., Levchenko, A., Pereira, S., Pascual, B., Bradbury, K., Arbones, V., Fong, J., Shulman, J. M., McGuire, A. L., and Masdeu, J., “Research Participants' Perspectives on Precision Diagnostics for Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 3, pp. 1261-1274, 2024.
G. Alva, Cubała, W. J., Berrio, A., Coate, B., Abler, V., and Pathak, S., “Safety Profile of Pimavanserin Therapy in Elderly Patients with Neurodegenerative Disease-Related Neuropsychiatric Symptoms: A Phase 3B Study.”, J Alzheimers Dis, vol. 98, no. 1, pp. 265-274, 2024.
G. Alva, Cubała, W. J., Berrio, A., Coate, B., Abler, V., and Pathak, S., “Safety Profile of Pimavanserin Therapy in Elderly Patients with Neurodegenerative Disease-Related Neuropsychiatric Symptoms: A Phase 3B Study.”, J Alzheimers Dis, vol. 98, no. 1, pp. 265-274, 2024.
K. Duff, Hammers, D. B., Koppelmans, V., King, J. B., and Hoffman, J. M., “Short-Term Practice Effects on Cognitive Tests Across the Late Life Cognitive Spectrum and How They Compare to Biomarkers of Alzheimer's Disease.”, J Alzheimers Dis, vol. 99, no. 1, pp. 321-332, 2024.
K. Duff, Hammers, D. B., Koppelmans, V., King, J. B., and Hoffman, J. M., “Short-Term Practice Effects on Cognitive Tests Across the Late Life Cognitive Spectrum and How They Compare to Biomarkers of Alzheimer's Disease.”, J Alzheimers Dis, vol. 99, no. 1, pp. 321-332, 2024.
A. Hambali, Jusril, N. Atiqah, Hashim, N. Fariesha M., Manan, N. Abd, Adam, S. Khadijah, Mehat, M. Zulfadli, Adenan, M. Ilham, Stanslas, J., and Hamid, H. Abdul, “The Standardized Extract of Centella asiatica and Its Fractions Exert Antioxidative and Anti-Neuroinflammatory Effects on Microglial Cells and Regulate the Nrf2/HO-1 Signaling Pathway.”, J Alzheimers Dis, vol. 99, no. s1, pp. S119-S138, 2024.
M. O. Etekochay, Amaravadhi, A. Rao, González, G. Villarrubi, Atanasov, A. G., Matin, M., Mofatteh, M., Steinbusch, H. Wilhelm, Tesfaye, T., and Praticò, D., “Unveiling New Strategies Facilitating the Implementation of Artificial Intelligence in Neuroimaging for the Early Detection of Alzheimer's Disease.”, J Alzheimers Dis, vol. 99, no. 1, pp. 1-20, 2024.
J. Rodrigo Do Santos, Catalão, C. Henrique R., Vulczak, A., Azzolini, A. Elisa Cale, and Alberici, L. Carla, “Voluntary wheel running decreases amyloidogenic pathway and rescues cognition and mitochondrial energy metabolism in middle-aged female 3xTg-AD mouse model of Alzheimer's disease.”, J Alzheimers Dis, vol. 102, no. 2, pp. 424-436, 2024.
2025
H. Tong, Petyuk, V. A., Sendtner, M., Sood, A., Bennett, D. A., Capuano, A. W., and Arvanitakis, Z., “Alzheimer's disease-related cortical proteins modify the association of brain insulin signaling with cognitive decline.”, J Alzheimers Dis, vol. 104, no. 3, pp. 667-677, 2025.
H. Tong, Petyuk, V. A., Sendtner, M., Sood, A., Bennett, D. A., Capuano, A. W., and Arvanitakis, Z., “Alzheimer's disease-related cortical proteins modify the association of brain insulin signaling with cognitive decline.”, J Alzheimers Dis, vol. 104, no. 3, pp. 667-677, 2025.

Pages